Skip to content

Study on Safety and Efficacy of Triphala recipes extract in normal volunteers and dyslipidemia patients

Study on Safety of Triphala recipes Extract in Normal Volunteers (Clinical Trial Phase I) and Comparative Study of Efficacy and Adverse Effects of Triphala recepies Extract versus Simvastatin in Blood Lipids Reduction in Dyslipidemia Patients (Cl

Status
Recruiting
Phases
Phase 1Phase 2
Study type
Interventional
Source
TCTR
Registry ID
TCTR20180423002
Enrollment
76
Registered
2018-04-23
Start date
2017-07-06
Completion date
Unknown
Last updated
2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Phase I : Healthy volunteers Phase II : Dyslipidemia patients Dyslipidemia

Interventions

The preparation of Triphala was produced and quality controlled was performed at Phamaceutica Chemistry and Natural Products&#44
Mahasarakham University&#44
Thailand.,The Simvastatin(10 mg) was purchased from The Government Pharmaceutical Organization&#44
prepared and quality controlled was performed at Phamaceutica Chemistry and Natural Products&#44
Experimental Drug,Active Comparator Drug
Triphala recipes Extract ,Simvastatin

Sponsors

Thai Traditional Medicinal Knowledge Fund
Lead Sponsor
Thammasat university
Collaborator

Eligibility

Sex/Gender
All
Age
20 Years to 65 Years

Inclusion criteria

Inclusion criteria: Phase I 1. Male or female 2. Aged 20 – 65 years old 3. Must be healthy 4. No pregnancies and breast-feeding 5. Not participate in other research project 6. No smoking, drug, alcohol and other supplement Phase II 1. Male or female. 2. Aged 20 – 65 years old. 3. Total Cholesterol and LDL-C are above optimal level to borderline high : 200-239 mg/dl or LDL-C 100-159 mg/dl 5. Has been diagnosed with dyslipidemia but has not been prescribed medication by medical doctor. 6. Laboratories results such as AST, ALT,BUN, Creatinine,CBC are normal.

Exclusion criteria

Exclusion criteria: Phase I and II 1. Taking other oral medicine. 2. Medicinal and herbal sensitivities. 3. Having severe illness history

Design outcomes

Primary

MeasureTime frame
Safety outcome 1 month Sign, symptom and laboratory result

Secondary

MeasureTime frame
Efficacy outcome 3 months Sign, symptom and laboratory result

Countries

Thailand

Contacts

Public ContactPraty Phetkate

Chulabhorn International College of Medicine, Thammasat University

rlon_game@hotmail.com0888929556

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Apr 4, 2026